TENORMIN (atenolol)

TENORMIN® (atenolol), a synthetic, beta1-selective (cardioselective) adrenoreceptor blocking agent, may be chemically described as benzeneacetamide, 4 -[2'-hydroxy-3'-[(1- methylethyl) amino] propoxy]-. The molecular and structural formulas are:

C₁₄H₂₂N₂O₃ Atenolol (free base) has a molecular weight of 266. It is a relatively polar hydrophilic compound with a water solubility of 26.5 mg/ mL at 37°C and a log partition coefficient (octanol/water) of 0.23. It is freely soluble in 1N HCl (300 mg/mL at 25°C) and less soluble in chloroform (3 mg/mL at 25°C).
TENORMIN (atenolol tablets) is available as 25, 50 and 100 mg tablets for oral administration.
Inactive Ingredients: Magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate.

HEPADIAL Biocodex/Hllton

HEPADIAL Biocodex/Hllton

1digg

Drug Category: Choleretic agent.

Generic Name: Dimecrotic acid.

Contents: Tabs: Dimecrotic acid 50mg (magne­sium salt).

Indications: Hepato digestive insufficiency and its manifestations (Dyspepsia, nausea, hedache of digestive organs). Food intoxication, biliary dyski-nesia. Sequelae of viral hepatitis. Constipation. Post-chiolecystectomy. Hepatic protection of alco­holics.

Dosage: Adults: 3 or 4 tabs daily, to be swallowed at meal time.  Children: Not recommended.

Contra-Ind: Bile duct obstruction and severe hepa-tocellular failure.

MODIUM Janssen-Cilag

MODIUM Janssen-Cilag

digg

Drug Category: Opiate

Generic Name: Loperamide HCI.

Contents: Caps: Loperamide HCI 2mg.

Indications: Diarrhoea.

Dosage: Adults: Acute diarrhoea: initially 2 caps, then 1 at each loose stool (usually 3-4 daily). Max, 8 daily.

Chronic diarrhoea: initially 2-4 caps, daily in divided doses.

Children: Acute diarrhoea: 9-12 years, 1 cap four times daily.

Precautions: Severe acute ulcerative colitis.

Adverse effects: Rashes.

LANSOR Pharmedic

LANSOR Pharmedic

0digg

Drug Category: Proton pump inhibitor

Generic Name: Lansoprazole.

Contents: Caps: Lansoprazole 30mg.

RISEK Getz Pharma

RISEK Getz Pharma

0digg

Drug Category: Proton pump inhibitor.

Generic Name: Omeprazole.

Contents: Caps: Omeprazole 20mg.

Infusion: Per Vial: Omeprazole sodium 42.6mg equivalent to omeprazole 40mg.

QALSAN Novartis

QALSAN Novartis

0digg

Drug Category: Calcium supplement.

Generic Name: Calcium carbonate.

Contents: Chewable Tabs: Cacium carbonate USP 1250mg (500mg elemental calcium); sugar free (contains aspartame).

Indications: Raised calcium requirements, e.g. during pregnancy, lactation, children and adoles­cents at times of rapid growth. Inadequate intake of calcium in diet. Osteoporosis. As a supplement to vit D in treatment of rickets and osteomalacia. Latent tetany.

Dosage: Adults & Children: As a supplement to diet 1 tab daily. The dosage may be increased when there is higher demand for calcium e.g. pregnancy, lactation etc.

Contra-ind: Hypercalcaemia, hypercalciuria, se­vere renal failure, renal calculi, galactosaemia.

Precautions: In renal impairment, electrolyte imbal­ance, monitor blood and urinary calcium levels.

Interactions: Cardiac glycosides (inj. only), thia-zides, tetracyclines.

Adverse effects: Diarrhoea.

NAVIDOXINE

NAVIDOXINE UCB

0digg

Drug Category: Antiemetic(piperazine deriva-tive)/vitamin.

Contents: Tabs: Meclizine 2HCI 25mg, vit B6 50mg.

Indications: Prophylaxis and treatment of nausea and vomiting in pregnancy.

Dosage: Adults: Once a day 1 or 2 tabs at bed­time.

TARIVID

TARIVID 200 mg Tablets
TARIVID 400 mg Tablets
TARIVID I.V. 200 mg




COMPOSITION :
TARIVID 200 mg Tablets:
Each tablet contains 200 mg Ofloxacin.
TARIVID 400 mg Tablets:
Each tablet contains 400 mg Ofloxacin.
TARIVID I.V. 200 mg:
Each 100 mL infusion solution contains 220 mg ofloxacin hydrochloride, equivalent to 200 mg Ofloxacin.

PHARMACOLOGICAL CLASSIFICATION:
A: 20.1.1 Broad and medium spectrum antibiotics.

PHARMACOLOGICAL ACTION:
TARIVID is a quinolone carboxylic acid derivative which has a broad spectrum of antibacterial activity against both Gram-positive and Gram-negative bacteria.
TARIVID exerts its effect by inhibiting the bacterial DNA gyrase, which is responsible for coiling the genetic material as a prerequisite for bacterial multiplication.
The mode of action, range of activities, duration of action and MIC levels have been established mainly by means of in vitro studies using bacterial isolates.
TARIVID is readily absorbed and excreted mainly unchanged in the urine.
The serum elimination half life is approximately 6-8 hours.
Following oral administration, TARIVID peak serum concentrations are reached within one to two hours.
The plasma level usually achieved by the recommended dosage regimen (3-4 micrograms/mL) is in excess of the average MIC which is 1-2 micrograms/mL, for susceptible organisms.
TARIVID has a low (9,4%) plasma protein binding.
TARIVID has a bactericidal effect.
In vitro tests show that strains in which the sensitivity varies include pneumococci and ureaplasma urealyticum.
Strains that are normally resistant are:
Peptococcus, Peptostreptococcus, Eubacterium spp., Fusobacterium spp. and Treponema pallidum.

INDICATIONS:
TARIVID is indicated for the treatment of the following bacterial infections if these are due to ofloxacin-sensitive pathogens:
Lower respiratory tract infections caused byHaemophilus influenzae, Haemophilus parainfluenzae, Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis and Pseudomonas aeruginosa.
Infections of the urinary tract.
Sexually transmitted diseases: Acute uncomplicated urethral and cervical gonorrhoea, urethritis and cervicitis due toChlamydia trachomatis. Mixed infections of the urethra and cervix due toChlamydia trachomatis and Neisseria gonorrhoea.
Prevention of colonisation by gram negative organisms as part of a multi-antimicrobial regimen in patients with neutropenia, secondary to cytostatic therapy.

CONTRA-INDICATIONS:
Hypersensitivity to ofloxacin or related chemotherapeutic agents of the quinolone-derivative group, or any of the excipients.
TARIVID should not be administered to pregnant or lactating women.
TARIVID should not be administered to patients with cerebral convulsive disorders.
TARIVID is contra-indicated in epileptics. TARIVID must not be used in patients with pre-existing central nervous system (CNS) lesions involving a lowered convulsant threshold, e.g. after cerebrocranial injuries, inflammations in the region of the CNS, or stroke.
In children or adolescents in the growth phase.
In patients with a history of tendon disorders related to fluoroquinolone administration.

WARNINGS:
Even when used as instructed, TARIVID may alter reactivity to such an extent that the ability to drive vehicles or operate machinery may be impaired.
Animal studies have shown that TARIVID may affect joint development in immature animals.
Tarivid should not be given to patients under 18 years of age.
Clostridium difficile - associated disease:
Diarrhoea, particularly if severe and/or persistent, occurring during treatment or in the initial weeks following treatment with ofloxacin or with various other antibiotics, but especially broad spectrum antibiotics, may be symptomatic of Clostridium difficile-associated disease, the most severe form of which is pseudomembranous colitis.
If a diagnosis of pseudomembranous colitis is suspected, ofloxacin should be stopped immediately and appropriate specified antibiotic therapy should be started without delay (e.g. vancomycin or metronidazole)
Tendinitis, less frequently observed, may occasionally lead to rupture, involving more particularly Achilles tendon, and occurring especially in elderly patients. Rupture seems to be favoured by treatment with corticosteroids. The onset of signs of tendinitis requires to stop the treatment, to rest both Achilles tendons by appropriate immobilization or special heel pieces, and to take orthopaedic advice.
Ofloxacin may aggravate myasthenia gravis.
Ofloxacin may inhibit the growth ofMycobacterium tuberculosis, giving false-negative results, in the bacteriological diagnosis of tuberculosis.
The serum concentration of ofloxacin should be monitored in patients with severe renal impairment and haemodialysis patients.
Although this has not been reported, the possibility cannot be ruled out that fluoroquinolones may trigger an attack of porphyria in predisposed patients.

DOSAGE AND DIRECTIONS FOR USE:
TARIVID TABLETS
TARIVID should be swallowed whole with a little liquid. It may be taken on an empty stomach or with meals.
If the treatment has been initiated via I.V. route, it is usually possible to switch to oral route at the same dosage after a few days, when the patients condition has improved.
The dosage should be determined according to the sensitivity of the causative organism and the severity of the infection.
The following dosages are recommended:
Uncomplicated Cystitis:
100 mg twice daily for 3-7 days.
Pyelonephritis:
200 mg twice daily for 5-7 days.
Infections of the lower respiratory tract:
400 mg twice daily for 7 -10 days. The daily dose may be altered depending on the severity of the infection.
Uncomplicated urethral and cervical gonorrhoea:
A single dose of 400 mg.
Urethritis and cervicitis due to Chlamydia trachomatis:
600 mg daily in divided doses for up to 7 days.
Prevention of infections in patients with neutropenia:
400 to 600 mg daily in divided doses.
It may be necessary to increase the dose to 600 mg or 800 mg ofloxacin daily in the presence of pathogens of varying sensitivity, in severe infections.

TARIVID I.V.
The dosage of TARIVID I.V. is determined by the severity and type of infection and the sensitivity of the causative organisms.
The usual dosage is 100-200 mg twice daily. For severe infections the dosage may be increased to 400 mg twice daily. Intravenous therapy should be discontinued as soon as oral TARIVID therapy can be substituted.
TARIVID I.V. should be infused SLOWLY over a period of 30-60 minutes.
TARIVID I.V. should be used as soon as the infusion vial has been opened. If its compatibility with other infusion solutions has not been proven, TARIVID I.V. should as a rule be administered separately.
TARIVID I.V. is compatible with the following infusion solutions:
Isotonic saline solution, Ringer’s solution, fructose solution 5%, glucose solution 5%.
Any unused portion of the I.V. solution must be discarded.
Heparin should not he administered in the same intravenous infusion fluid because of the risk of precipitation.
Impaired renal function:
For patients with impaired renal function and elderly patients the dosage of TARIVID should be adjusted according to the degree of impairment. With a creatinine clearance of less than 50 mL to 20 mL/min, a normal single dose should be administered every 24 hours, e.g. 200 mg once daily. With a creatinine clearance of less than 20 mL/min, the normal single dose should be given initially. This dose should then be reduced to half and administered every 24 hours, e.g. 200 mg initially, thereafter 100 mg once daily.
Dosage in patients with impaired liver function:
The excretion of ofloxacin may be reduced in patients with severe liver function disorders (e.g. cirrhosis of the liver with ascites). A maximum daily dose of 400 mg ofloxacin should therefore not be exceeded.

SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Effects on the gastro-intestinal tract:
Gastro-intestinal symptoms may occur (gastric or abdominal symptoms, loss of appetite, nausea, vomiting, diarrhoea). If severe and persistent diarrhoea occurs during or after therapy, the physician should be informed because in a few cases this may point to a serious intestinal disorder (pseudomembranous colitis which is generally due to Clostridium difficile - see WARNINGS) which requires immediate treatment. In such cases TARIVID must be discontinued immediately and suitable therapy initiated. Products inhibiting peristalsis are contra-indicated.
Effects on the central nervous system:
Disturbances of the nervous system, e.g. weakness, headaches, dizziness, sleep disturbances: insomnia, nightmares, drowsiness, unsteady gait and tremor (disturbances of muscular coordination), numbness and tingling (paresthesiae), visual disturbances such as blurred vision, double vision and abnormal colour vision, disturbances of the senses of taste and smell, hearing and equilibrium, psychotic reactions such as restlessness, agitation, anxiety, depression and confusion and hallucinations, sometimes progressing to self-endangering behaviour. These reactions have occurred mainly in elderly patients and patients with impaired renal function, but not exclusively. In some cases these reactions have occurred already after the first dose. In the event of such adverse reactions, TARIVID should be discontinued immediately and the doctor informed. Seizures, and less frequently extrapyramidal symptoms may occur.
Muco-cutaneous effects:
Allergic manifestations may occur, in particular hypersensitivity reactions of the skin such as pruritis, rash. Pustular eruption, single cases of bullous eruption (erythema multiforme, Stevens-Johnson syndrome or exceptionally, toxic epidermal necrolysis). Vascular purpura and systemic necrotising angeitis may occur in less frequent cases. There have been fleabite-like haemorrhages (petechiae), the formation of blood blisters (haemorrhagic bullae) and small nodules (papules) with crust formation indicating vessel involvement (vasculitis), allergic inflammation of the lungs (pneumonitis), and fever.
Skin reactions on exposure to strong sunlight, have been reported (photosensitisation). Therefore exposure to sunlight and UV radiation should be avoided during treatment with TARIVID.
With the administration of TARIVID I.V. local irritation, pain at the site of injection, phlebitis or thrombo-phlebitis have been observed.
Anaphylactoid or anaphylactic reactions:
Acute anaphylactic or anaphylactoid reactions may occur, sometimes even after the first dose. It may manifest as hypotension, (a fall in blood pressure), burning sensation in the eyes, tickling cough and nasal catarrh, swelling of the skin and mucous membranes involving the face, tongue and larynx (hoarseness, difficulty in breathing) respiratory distress (also caused by bronchial spasm) or circulatory collapse (shock) may develop. In the event of such reactions, treatment with TARIVID should be discontinued immediately. Medical treatment (therapy for shock) is imperative.
Effects on the blood:
There have been cases of changes in the blood picture (eosinophilia, neutropenia, leukopenia, agranulocytosis, thrombocytopenia, anaemia, pancytopenia, haemolytic anaemia, bone marrow depression)
Effects on the kidneys and liver:
Transient increases in liver enzymes (ALAT, ASAT, LDH, gamma-GT and/or alkaline phosphatase) and/or bilirubin or hepatitis may occur. Crystalluria may also occur, as well as increases in serum creatinine, interstitial nephritis sometimes progressing to acute renal failure.
Effects on the musculoskeletal system:
Myalgia and arthralgia (pain). Inflammation and rupture of tendons (e.g. the Achilles tendon may occur within 48 hours after starting the treatment and may be bilateral (see WARNINGS). This has occurred particularly in patients treated concurrently with corticosteroids. In the event of signs of inflammation of a tendon, treatment with TARIVID must be discontinued immediately and appropriate treatment for the affected tendon, initiated. Less frequently cases of myopathy and/or rhabdomyolysis may occur.
Others:
Less frequently, hypoglycaemia in diabetics treated with hypoglycaemic agents may occur.
Treatment with ofloxacin may enhance development of resistant micro organisms and fungal growth.
TARIVID may result in an acceleration of the heart beat as well as a decrease in blood pressure which may be severe particularly after infusions and especially when given too rapidly. In the event of a serious decrease in blood pressure TARIVID I.V. should be discontinued. In less frequent cases, as a consequence of a pronounced drop in blood pressure, circulatory collapse may occur. Blood pressure should be monitored frequently during the infusion.
Experience to date shows that the adverse reaction to TARIVID treatment resolves on discontinuation of the preparation. The physician should always be informed of side-effects that have occurred.

Interactions:
Antacids containing aluminium, including sucralfate, and magnesium hydroxides, aluminium phosphate or calcium, zinc, iron are liable to reduce the absorption of TARIVID. In such cases TARIVID should be taken about 2 hours before taking such preparations.
There are indications of a pronounced lowering of the cerebral seizure threshold when quinolones are given concurrently with other medicines that lower the seizure threshold, e.g. theophylline. The possibility cannot be ruled out with certainty that during treatment with TARIVID, as with other quinolones, the effect of coumarin derivatives may be intensified. Patients undergoing concomitant treatment with coumarin derivatives should therefore be monitored carefully.
Excessive rises or falls in blood-sugar level may occur in isolated cases, especially in patients with diabetes mellitus. Ofloxacin may cause a slight increase in serum concentrations of glibenclamide if administered concurrently, it is therefore recommended that patients treated concomitantly with TARIVID and glibenclamide be monitored particularly closely.
The concomitant use of TARIVID I.V. and hypotensive medicines and barbiturates may cause a fall in blood pressure.
Particularly in case of high dose therapy, mutual impairment of excretion and an increase in serum levels must be considered when quinolones are administered together with other medicines that also undergo renal tubular secretion (such as probenecid, cimetidine, furosemide or methotrexate)

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT:
See side-effects and special precautions. The most important signs to be expected following acute overdosage are CNS symptoms such as confusion, dizziness, impairment of consciousness and seizures as well as gastro-intestinal reactions such as nausea and mucosal erosions. In the event of overdose, gastric lavage and symptomatic treatment should be implemented. No specific antidote exists.

IDENTIFICATION:
TARIVID 200 mg Tablet: A pale, yellowish-white, oblong, biconvex, film-coated tablet, scored on both sides with MXI imprinted on one side of the score and the company logo on the other side. On the other side of the tablet the imprint is reversed.
TARIVID 400 mg Tablet: A pale, yellowish-white, oblong, biconvex, film-coated tablet, scored on both sides. Both sides imprinted MXL and the company logo.
TARIVID I.V. 200 mg: A clear, slightly yellow solution in a 100 mL infusion vial.

PRESENTATION:
TARIVID 200 mg Tablets: Cardboard containers with opaque blister packs containing 6, 10 or 100 tablets each.
TARIVID 400 mg Tablets: Cardboard containers with one or more opaque blister packs of 10 tablets each.
TARIVID I.V. 200 mg: 5 Infusion vials of 100 mL.

STORAGE INSTRUCTIONS:
Store below 25°C in a dry place.
Protect from light. Keep in the pack until required.
Once the infusion vial has been opened, the infusion solution must be used without delay.
Do not use later than the date of expiry.
Keep out of reach of children.

REGISTRATION NUMBERS:

TARIVID 200 mg Tablets:	V/20.1.1/252
TARIVID 400 mg Tablets:	27/20.1.1/0162
TARIVID I.V. 200 mg:	Z/20.1.1/336

ENTAMIZOLE Abbott

ENTAMIZOLE Abbott

0digg

Drug Category: Amoebicide.

Contents: DS Tabs: Diloxanide furoate 500mg, metronidazole 400mg.

Susp: Per 10ml: Diloxnide furoate 250mg, met­ronidazole benzoate 320mg equiv to metronidazole 200mg.Tabs: Diloxanide furoate 250mg, metronidazole 200mg.

Indications; Amoebiasis, and other systemic dis­ease due to other E. histolytica. Giardiasis.

Dosage: Adults: 2 tabs or 1 DS tab or 10-20ml thrice daily for 5 days. Children: 5-12 years, Half to one Entamizole Tab or 5-10ml thrice daily for 5 days; 1-5 years, 5ml thrice for 5 days. In refractory cases the treatment in adults and children can be continued for 10 days.

Precautions: Avoid during pregnancy.

Interactions: Anticoagulants, phenobarbitone, al­cohol.

Adverse effects: Gl distress.

URIXIN ABBOTT

URIXIN Ingredient(s): Each tablet contains Pipemidic Acid 400 mg

Indications : Urixin is indicated in the treatment of acute (simple) and chronic (complicated) urinary tract infections caused by E.coli, Proteus, Klebsiella, Pseudomones ariginosa, Enterobacter, Citrobacter or Staphylococus. Urixin is indicated in the treatment of bacillary dysentery and enteritis caused by Shigella ssp, Salmonella ssp, Vibrio parahemolytius, E.coli, Klebsiella ssp, Citrobecter ssp, Enterobecter ssp, Proteus ssp and pseudomonas ssp.

Pack Size:    10x10s in carton

ARTIFEN Abbott

0digg

Drug Category: Phenylacetic acid.

Generic Name: Diclofenac sodium.

Contents: Inj: Diclofenac sodium 25mg per ml in 3ml amp. Tabs 25mg/50mg: Diclofenac sodium.

Indications :

• The treatment of pain and inflammation in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and in other musculoskeletal disorders including periarthritis, bursitis, tendonitis, tenosynovitis, sprains, strain and dislocation.
• The control of pain and inflammation in minor surgery.
• The control of pain and inflammation in acute gout.
• The treatment of pain and inflammation of chronic juvenile arthritis.

CAFLAM Novartis

CAFLAM Novartis

0digg

Drug Category: Phenylacetic acid.

Generic Name: Diclofenac potassium.

Contents: Tabs 50mg: Diclofenac potassium 50mg.

Indications: Short-term treatment in the following acute conditions: Painful post-traumatic inflamma­tory states. Post- operative inflammation and pain. Painful and/or inflammatory conditions in gynae­cology. Painful syndromes of the vertebral col­umn. Non-articular rheumatism. As adjuvant in severe painful inflammatory infections of the ear, nose and throat. (Fever alone is not an indication).

Dosage: Adults: 75-150mg daily in 2-3 doses (dysmenorrhoea up to 200mg).

Children: Over 1 year, 0.5- 2mg/kg body-wt. daily in divided doses.

Contra-ind: Active peptic ulcer. Hypersensitivity to aspirin or other prostaglandin synthesis-inhibiting drugs.

Precautions: Monitor patients on long-term treat­ment. History of gastro-intestinal disease. Renal, hepatic or cardiac insufficiency. Pregnancy, lacta­tion. Porphyria. Patient with extracellular volume depletion from any cause. On longterm therapy monitor liver function, blood counts. Elderly.

Interactions: Anticoagulants, antidiabetics, diuretics.

Adverse effects: Gastro-intestinal disorders, head­ache, dizziness, vertigo, rash, elevation of SGOT, SGPT. Peptic ulcer, gastro-intestinal bleeding, hepatitis, hypersensitivity reactions. Disturbances of sensation, erythema multiforme. purpura. ab­normalities of renal function, blood dyscrasias.

CREMAFFIN Abbott

CREMAFFIN Abbott
Drug Category: Laxative.
Contents: Emulsion: Mist magnesium hydroxide 75% v/v, liquid paraffin 25% v/v.
Indications: Constipation, hyperacidity.
Dosage: Adults: 20ml.
Regn.No:Pack:Trade Prices:Retail Prices:
Emulsion (000077): 120ml: 15.56:18.30

SILLIVER Abbott

SILLIVER Abbott
Drug Category: Lipotropics/cholagogues.
Contents: Tabs: Silymarin 200mg.
Indication: As a supportive therapy for liver dis­eases e.g. jaundice, hepatitis, hepatic cirrhosis.
Dosage: Adults & Children: 1 tab twice daily.
Regn.No:Pack:Trade Prices:Retail Prices:
Tabs(023930):15's: 81.77:96.20.
Indications: Silymarin is indicated as adjunctive therapy in the treatment of liver disease of varying etiologies; acute hepatitis, chronic persistent and chronic aggressive hepatitis, cirrhosis of the liver, fatty liver, toxic metabolic or toxic metabolic liver damage. It has been shown to protect the liver from damage caused by general anesthesia. 

LILAC Getz Pharma

Drug Category: Osmotic laxative. Generic Name: Lactulose. Contents: Syp: Per 5ml: Lactulose 3.35gm.

Lactulose side effects Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using lactulose and call your doctor at once if you have severe or ongoing diarrhea. Less serious side effects may include: bloating, gas; stomach pain; diarrhea; or nausea, vomiting.

Kemadrin (procyclidine)

Kemadrin tablets and injection contain the active ingredient procyclidine hydrochloride, which is a type of medicine called an anticholinergic. (NB. Procyclidine is also available without a brand name, ie as the medicine.) Anticholinergic medicines (sometimes also called antimuscarinics) work by preventing the activity of a neurotransmitter called acetylcholine.
Neurotransmitters are chemical compounds that are found in the brain and nerves. They act as chemical messengers between the nerve cells. There are many different neurotransmitters in the body and these have various different functions. Several diseases and conditions involve either overactivity or underactivity of certain neurotransmitters.
In Parkinson’s disease, there is a deficiency of a neurotransmitter called dopamine in the brain. Normally there is a balance between the activity of dopamine and the activity of acetylcholine in the brain. However, in Parkinson's disease, the deficiency of dopamine causes overactivity of acetylcholine. This causes some of the symptoms of the disease.
Procyclidine works by blocking the receptors that acetylcholine acts on. This reduces the activity of the acetylcholine, and helps restore the balance of acetylcholine and dopamine in the brain. In this way, procyclidine helps control some of the symptoms of Parkinson's disease. It is most effective at reducing the tremor and rigidity associated with the disease, but it has little effect on the slow movements (bradykinesia).

THERAGRAN-M

COMPOSITION
Each THERAGRAN-M tablet supplies: Vitamin A 10 000 i.u.; Vitamin D 400 i.u.; Vitamin B110 mg; Vitamin B210 mg; Vitamin B65 mg; Vitamin B125 mcg; Niacinamide 100 mg; Calcium Pantothenate 20 mg; Vitamin C 200 mg; Vitamin E 15 i.u.; Iodine 0,15 mg; Iron 12 mg; Copper 2 mg; Manganese 1 mg; Magnesium 65 mg; Zinc 1,5 mg.

PHARMACOLOGICAL CLASSIFICATION
Category A 22.1 Multivitamins and multivitamins with minerals.

INDICATIONS
THERAGRAN-M is indicated in mixed vitamin deficiencies. THERAGRAN-M supplies high potency dosages of vitamins required in chronic vitamin deficiency states, and is of clinical importance when high potency nutritional support is indicated in special medical situations.

THERAGRAN-M contains all the essential vitamins for an extended vitamin coverage of multiple deficiencies resulting from unbalanced diets, pregnancy, old age, infections. convalescence and adolescence.

WARNINGS
Not to be used by persons who are allergic to iodine.

DOSAGE AND DIRECTIONS FOR USE
Adult dosage is 1 tablet daily. Do not exceed the recommended dose unless prescribed by a doctor.

KNOWN SYMPTOMS OF OVERDOSAGE AND PARTICULARS OF ITS TREATMENT
Treatment of overdosage should be symptomatic and supportive.

IDENTIFICATION
A maroon coloured, capsule shaped, sugar coated tablet with an odour of vanillin.

PRESENTATION
Bottles of 30 tablets.

BRUFEN

Category: Non Steroidal Anti-Inflammatory Drugs (NSAIDs)
Form: Coated tablets / syrup
Scientific Name: Ibuprofen BP
License by: Abbott laboratories -


Dosage:
ADULTS: The recommended dosage of BRUFEN is 1200-1800 mg daily in divided doses. Some patients can be maintained on 600-1200 mg daily. In severe or acute conditions it can be advantageous to increase the dosage until the acute phase is brought under contr

Composition:
TABLETS: BRUFEN is available as sugar coated tablets containing either 200 mg (Brufen 200) or 400 mg (Brufen 400) Ibuprofen BP. It is also available as BRUFEN 600, film coated tablets each containing 600 mg of Ibuprofen BP. SYRUP: For children, and for ad

Indications and usage:
BRUFEN is indicated for its analgesic and anti inflammatory effects in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthr
 

DESERTIC

Dosage:
To minimize dose-independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapy. Hydrochlorothiazide is effective in doses of 12.5 to 50 mg once daily. Candes

Composition:
Each Tablet contains: 16 mg Candesartan cilexetil + 12.5 mg Hydrochlorothiazide. Or 32 mg of Candesartan cilexetil + 12.5 mg of Hydrochlorothiazide.

Indications and usage:
DESERTIC is indicated for the treatment of hypertension.

CAPOTEN

Dosage:
CAPOTEN (captopril) should be taken one hour before meals. Dosage must be individualized. Hypertension: Initiation of therapy requires consideration of recent antihypertensive drug treatment, the extent of blood pressure elevation, salt restriction, and o

Composition:
CAPOTEN (captopril) is available in potency of 25 mg and 50 mg, as scored tablets for oral administration.

Indications and usage:
Hypertension: CAPOTEN (captopril) is indicated for the treatment of hypertension,Captopril is effective alone and In combination with other anti hypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captoprit and

LEFLOX Getz Pharma

Drug Category: Quinolone.

 Generic Name: Levofloxacin

Contents: Infusion: Per ml: Levofloxacin 5mg;100ml(500mg)soln.

Tabs 250mg/500mg: Levofloxacin 250mg/500mg (as levofloxacin hemihydrate).

Broad spectrum antibiotic for the treatment of bacterial infections such as pneumonia, chronic bronchitis and sinusitis, urinary tract infections and skin infections.

NEUROBION Merck Marker

NEUROBION Merck Marker

0digg

Drug Category: Vitamin.

Contents: Inj: Per 3ml amp: Vits B1 100mg, B6 100mg, B12 1000mcg. Tabs: Vits B1 100mg, B6 100mg, B12 200mcg.

Indications: Neuralgia and neuritis of toxic and non-toxic origin.

Dosage: Inj: Adults: 1 Inj daily or on alternate days.

Tabs: Adults: 3 tabs daily.

Neurobion is a combination of Neurotropic vitamins B1, B6, & B12 these vitamins in their role as co-enzymes are indispensable factors in the metabolism of the nervous system. Neurobion normalizes the nerve cell metabolism. Neurobion supports the regeneration of nerve fibre and myelin sheath by activation of the metabolism and the natural repair mechanism.
Neurobion is indicated in mono and polyneuropathies of any origin such as diabetic, alcoholic or toxic neuropathies. Neuritis or Neuralgia, especially cervical syndrome, shoulder- arms syndrome, Lumbago, sciatica and herpes zoster.